Perbandingan Efektivitas Levamisole versus Mycophenolate Mofetil Sebagai Terapi Sindrom Nefrotik Pada Anak

Sri Rahmat Molidia; Rizka Maulidiah

doi:10.56359/pharmgen.v4i3.922

Authors

Sri Rahmat Molidia Universitas Tanjungpura
Rizka Maulidiah Universitas Aisyiyah Palembang

DOI:

https://doi.org/10.56359/pharmgen.v4i3.922

Keywords:

Efektivitas, Levamisole, Mycophenolate Mofetil, Pediatri, Sindrom Nefrotik

Abstract

Pendahuluan: Jelaskan latar belakang penelitian secara singkat.

Tujuan: Penelitian ini dilakukan untuk membandingkan efektivitas antara Mycophenolate Mofetil dan levamisole agar bisa dijadikan referensi acuan dalam pemilihan pengobatan yang lebih efektif pada anak dengan sindrom nefrotik

Metode: Penelitian ini dilakukan dengan metode checklist PRISMA menggunakan database ScienceDirect, PubMed, dan Springer

Hasil: Berdasarkan enam jurnal yang dianalisis, didapatkan bahwa terapi Mycophenolate Mofetil (MMF) dan Levamisole sama efektif sebagai steroid-sparing agent pada anak-anak dengan sindrom nefrotik relaps sering maupun tergantung steroid. Kedua obat secara signifikan dapat menurunkan frekuensi relaps dan kebutuhan dosis kumulatif kortikosteroid tanpa efek samping berat. Beberapa penelitian menunjukkan bahwa MMF lebih unggul dalam mempertahankan remisi jangka panjang, sedangkan Levamisole memiliki profil keamanan dan biaya terapi yang lebih baik.

Kesimpulan: MMF dan Levamisole sama efektifnya untuk menurunkan relaps dan kebutuhan steroid pada sindrom nefrotik anak, akan tetapi MMF lebih unggul mempertahankan remisi, sedangkan Levamisole lebih aman, terjangkau, dan sesuai untuk terapi jangka panjang

References

Alsaran, K., Khalid, M., Al-Talhi, A., & Al-Kanani, E. (2017). Experience with second line drugs in frequently relapsing and steroid dependent childhood nephrotic syndrome in a large Saudi center. International Journal of Pediatrics and Adolescent Medicine, 4(2), 66–70. https://doi.org/10.1016/j.ijpam.2017.03.002

Basu, B., Pandey, R., Mahapatra, T. K. S., Mondal, N., & Schaefer, F. (2015). WITHDRAWN: Efficacy and Safety of Mycophenolate Mofetil Versus Levamisole in Children and Adolescents With Idiopathic Nephrotic Syndrome: Results of a Randomized Clinical Trial. American Journal of Kidney Diseases. https://doi.org/10.1053/j.ajkd.2015.04.048

Carter, S. A., Mistry, S., Fitzpatrick, J., Banh, T., Hebert, D., Langlois, V., Pearl, R. J., Chanchlani, R., Licht, C. P. B., Radhakrishnan, S., Brooke, J., Reddon, M., Levin, L., Aitken-Menezes, K., Noone, D., & Parekh, R. S. (2020). Prediction of Short- and Long-Term Outcomes in Childhood Nephrotic Syndrome. Kidney International Reports, 5(4), 426–434. https://doi.org/10.1016/j.ekir.2019.12.015

Chan, E. Y. hin, & Boyer, O. (2025). Childhood idiopathic nephrotic syndrome: recent advancements shaping future guidelines. In Pediatric Nephrology (Vol. 40, Issue 8, pp. 2431–2442). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s00467-024-06634-9

Floege, J., Gibson, K. L., Vivarelli, M., Liew, A., Radhakrishnan, J., & Rovin, B. H. (2025). KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. Kidney International, 107(5), S241–S289. https://doi.org/10.1016/j.kint.2024.11.007

Mazo, A., Kilduff, S., Pereira, T., Solomon, S., Matloff, R., Zolotnitskaya, A., & Samsonov, D. (2024). Mycophenolate Mofetil Versus Prednisone for Induction Therapy in Steroid-Sensitive Idiopathic Nephrotic Syndrome in Children: An Observational Study. Kidney Medicine, 6(3). https://doi.org/10.1016/j.xkme.2023.100776

Moorani, K. N., Hotchandani, H. M., Zubair, A. M., Lohana, N. C., & Veerwani, N. R. (2019). Immunosuppressive therapy in children with primary nephrotic syndrome: Single center experience, Karachi, Pakistan. BMC Nephrology, 20(1). https://doi.org/10.1186/s12882-019-1347-5

Noone, D. G., Iijima, K., & Parekh, R. (2018). Idiopathic nephrotic syndrome in children. The Lancet, 392(10141).

Sharma, S., Kalra, S., Shukla, S., & Sharma, P. (2022). Clinical efficacy of mycophenolate mofetil versus levamisole therapy in frequently relapsing and steroid dependent childhood nephrotic syndrome – A retrospective comparative analysis. Nephrology, 27(9), 758–762. https://doi.org/10.1111/nep.14067

Singh, J., Afzal, K., & Abqari, S. (2020). Daily Levamisole versus Mycophenolate Mofetil in Patients with Frequently Relapsing or Steroid Dependent Nephrotic Syndrome: An Open Label Non-inferiority Randomized Controlled Trial. Asian Journalof Pediatric Nephrology. https://doi.org/10.4103/AJPN.AJPN_5_20

Sinha, A., Puraswani, M., Kalaivani, M., Goyal, P., Hari, P., & Bagga, A. (2019). Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Kidney International, 95(1), 210–218. https://doi.org/10.1016/j.kint.2018.08.039

Vivarelli, M., & Emma, F. (2019). Levamisole for children with nephrotic syndrome: new evidence for the use of an “old” drug. In Kidney International (Vol. 95, Issue 1, pp. 25–28). Elsevier B.V. https://doi.org/10.1016/j.kint.2018.10.008

Webb, N. J. A., Woolley, R. L., Lambe, T., Frew, E., Brettell, E. A., Barsoum, E. N., Trompeter, R. S., Cummins, C., Deeks, J. J., Wheatley, K., & Ives, N. J. (2019). Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: Phase III randomised controlled trial and economic evaluation. The BMJ, 365. https://doi.org/10.1136/bmj.l1800